Table 3 Comparison of LIPS and serum biomarker levels at different time points among the groups.

From: Risk assessment of pARDS in severe pneumonia patients based on lung injury prediction scores and serum biomarkers

Variable

IL-8 (pg/mL)

vWF (µg/mL)

SP-D (ng/mL)

KL-6(ng/mL)

LIPS

T1

Control

11.0 (3.6, 16.1)

3.0 (1.7, 4.3)

94.6 (78.0,107.3)

1.4 (1.0,2.4)

-

non-pARDS

31.3 (26.2, 63.8)

4.2 (2.5, 6.1)

124.0 (105.9,144.9)

2.1 (1.5,2.7)

5.5 (5.0,6.5)

pARDS

49.5 (31.4, 72.5)bc

5.9 (4.1, 6.9)bc

144.5 (137.7,158.6)bc

3.2 (2.3,4.0)bc

7.3 (6.4,8.1)bc

T2

pARDS

70.6 (60.9, 123.7)d

7.0 (5.8, 8.3)d

169.2 (152.7,184.4)d

5.8 (3.9,7.2)d

8.5 (7.0,10.0)d

  1. b: P < 0.01 compared with the Control group; c: P < 0.05 compared with the non-pARDS group; d: P < 0.05 compared between T2 and T1 in the pARDS group; pARDS: pediatric acute respiratory distress syndrome; non-pARDS: non-pediatric acute respiratory distress syndrome; IL-8: interleukin-8; vWF: von willebrand factor; SP-D: surfactant protein D; KL-6: krebs von den lungen-6; LIPS: lung injury prediction score.
Back to article page